Intra-Cellular Therapies Inc
Change company Symbol lookup
Select an option...
ITCI Intra-Cellular Therapies Inc
IART Integra Lifesciences Holdings Corp
R Ryder System Inc
AAPL Apple Inc
IIM Invesco Value Municipal Income Trust
QQQ Invesco QQQ Trust
VZ Verizon Communications Inc
CHTR Charter Communications Inc
SPB Spectrum Brands Holdings Inc
USB US Bancorp
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Price
Delayed
$52.20
Day's Change
-1.38 (-2.57%)
Bid
--
Ask
--
B/A Size
--
Day's High
54.20
Day's Low
51.24
Volume
(Below Average)

Today's volume of 656,373 shares is on pace to be lower than ITCI's 10-day average volume of 1,016,423 shares.

656,373

Display:

Providers:

UpdateCancel
6 providers
August 09, 2022
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second quarter 2022 were $55.1 million, representing a 190%...(Globe Newswire)

August 04, 2022
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Intra-Cellular Therapies, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI). (PR Newswire)

August 02, 2022
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast

EQNX::TICKER_START (NASDAQ:ITCI), EQNX::TICKER_END Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today...(Globe Newswire)

June 24, 2022
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or...(Newsfile)

June 18, 2022
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 18, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofIntra-Cellular Therapies, Inc. ("Intra-Cellular" or "the Company")...(Accesswire)

June 16, 2022
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or "the Company") (NASDAQ: ITCI) for violations of the...(BusinessWire)

June 13, 2022
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience

EQNX::TICKER_START (NASDAQ:ITCI), EQNX::TICKER_END Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.